RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With
East Asia
Japan
Plasma biopsy
Treatment outcome
Vascular endothelial growth factor receptor-2
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
16
12
2021
revised:
14
02
2022
accepted:
19
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated Period 1 evaluated RAM (10 mg/kg) plus GEF (250 mg/d) in patients with untreated From December 2017 to August 2018, a total of 82 patients were enrolled and started treatment (period 1, RAM + GEF). The 1-year PFS rate was 62.9% (95% confidence interval: 50.3-73.1). Treatment-emergent adverse events of grade three or higher were reported with RAM plus GEF in 60 of 82 patients (73.2%; five patients [6.1%] grade four). There were two deaths owing to adverse events that occurred (acute cardiac failure, congestive cardiac failure). T790M rate at disease progression in plasma was 81.0% (13 of 16 patients). RELAY+ was found to have a favorable benefit-risk profile for RAM plus GEF in first-line treatment of East Asian patients with
Identifiants
pubmed: 35369607
doi: 10.1016/j.jtocrr.2022.100303
pii: S2666-3643(22)00027-3
pmc: PMC8966141
doi:
Banques de données
ClinicalTrials.gov
['NCT02411448']
Types de publication
Journal Article
Langues
eng
Pagination
100303Informations de copyright
© 2022 The Authors.
Références
Int J Clin Oncol. 2019 Jul;24(7):731-770
pubmed: 31049758
J Clin Oncol. 2018 Aug 1;36(22):2244-2250
pubmed: 29864379
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141884
Lancet Oncol. 2016 May;17(5):577-89
pubmed: 27083334
J Thorac Oncol. 2014 Feb;9(2):154-62
pubmed: 24419411
Lancet Oncol. 2017 Nov;18(11):1454-1466
pubmed: 28958502
Lancet Oncol. 2019 May;20(5):625-635
pubmed: 30975627
Lancet Oncol. 2014 Oct;15(11):1236-44
pubmed: 25175099
Lung Cancer. 2015 Apr;88(1):74-9
pubmed: 25704957
JTO Clin Res Rep. 2020 Oct 12;2(1):100107
pubmed: 34589972
Jpn J Clin Oncol. 2016 May;46(5):462-7
pubmed: 26977054
Clin Lung Cancer. 2006 Dec;8 Suppl 1:S31-5
pubmed: 17239288
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
J Thorac Oncol. 2019 Jan;14(1):99-106
pubmed: 30240852
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
J Clin Oncol. 2008 Dec 1;26(34):5589-95
pubmed: 18794545
J Thorac Oncol. 2015 Mar;10(3):486-91
pubmed: 25695221
JTO Clin Res Rep. 2021 Apr 16;2(6):100171
pubmed: 34590023
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Lancet Oncol. 2019 Dec;20(12):1655-1669
pubmed: 31591063
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
Nat Rev Cancer. 2007 Mar;7(3):169-81
pubmed: 17318210
Ann Oncol. 2017 Sep 01;28(9):2248-2255
pubmed: 28911086
Ann Oncol. 2015 Sep;26(9):1883-1889
pubmed: 26105600
J Clin Oncol. 2001 Jul 1;19(13):3267-79
pubmed: 11432895
Ann Oncol. 2019 Feb 1;30(2):171-210
pubmed: 30596843
Oncol Ther. 2018 Dec;6(2):203-215
pubmed: 32700028
Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1254-61
pubmed: 26070531
Cancer Sci. 2020 Dec;111(12):4510-4525
pubmed: 32954593
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
pubmed: 15741570
BMC Cancer. 2018 Aug 2;18(1):780
pubmed: 30068310
Onco Targets Ther. 2019 Jul 01;12:5097-5109
pubmed: 31303765
Skin Appendage Disord. 2015 Mar;1(1):31-7
pubmed: 27171241
Ann Oncol. 2003 Jun;14(6):922-30
pubmed: 12796031
Curr Oncol Rep. 2012 Aug;14(4):285-94
pubmed: 22544560
Ann Oncol. 2018 Jan 1;29(suppl_1):i3-i9
pubmed: 29462253
J Am Acad Dermatol. 2013 Sep;69(3):463-72
pubmed: 23602600
Clin Cancer Res. 2009 May 15;15(10):3484-94
pubmed: 19447865
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168